Market Data 
Markets
Replies to post #241644 on Avid Bioservices Inc (CDMO)
11/05/15 4:52 PM
11/05/15 5:26 PM
11/05/15 6:01 PM
SITC'15 PPHM's Booth #121...
NOTE: Join us for a Scientific Session - FRI Nov6 2015 7:30-9:00pm
“The PS Signaling Pathway: A Promising
Therapeutic Target Exploited by
Tumors for Immune Evasion”
PGM:
* Raymond Birge (PhD, Rutgers) birgelab.org
* Douglas Graham (MD, PhD, Emory) http://choa.org/Childrens-Hospital-Services/Cancer-and-Blood-Disorders/Meet-the-Team/Physicians-and-Researchers/Douglas-Graham
* Dmitry Gabrilovich (MD, PhD, Wistar Inst.) http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd
* Rolf Brekken (PhD, UTSW/Dallas) http://www.utsouthwestern.edu/labs/brekken
* Maria Karasarides (PhD, AstraZeneca - Sr. Director, ImmunoOncology, Global Medicines Dev.) http://www.linkedin.com/pub/maria-karasarides-ph-d/6/769/136
Emory, Children's name new chief of Aflac Cancer & Blood Disorders Center
Woodruff Health Sciences Center | Sept. 30, 2015
Children's Healthcare of Atlanta and Emory University announce that after 15 years of dedicated service, William G. Woods, MD, has stepped down as director of the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and chief of hematology/oncology/BMT in the Department of Pediatrics at Emory University. A nationwide search has identified Douglas Graham, MD, PhD, as the successor to this role. Dr. Graham joined Children's on August 17, 2015, and is working closely with Dr. Woods to ensure a successful transition.
"We are so thankful to Dr. Woods for his tremendous contributions to the Aflac Cancer Center," says Heather Davidson, vice president of hematology and oncology, Aflac Cancer Center. "Dr. Woods is a leader of great character, and everyone who has worked with him knows that our program would not be where it is today without his leadership. Under his tenure as director, the Aflac Cancer Center has grown in clinical and research faculty, grant funding, and research publications. His vision has led the Aflac Cancer Center to become one of the largest and most respected pediatric hematology/oncology programs in the country, now ranked by U.S. News & World Report among the top 10 pediatric cancer centers nationwide. He has truly built a legacy here."
Dr. Woods remains on faculty with the Aflac Cancer Center and Emory University. His new title is director emeritus.
"Dr. Graham brings to Children's a vision for the Aflac Cancer Center to enhance innovation and discovery across our core missions of clinical care, research and teaching," says Dr. Woods. "As we grow our program through new investment, recruitment and integration across our existing clinical and scientific expertise, Dr. Graham brings proven experience leading these missions. We are excited to have him join the team."
Dr. Graham is a member of the Senior Leadership Council of Winship Cancer Institute of Emory University. He will play a key role in helping to jointly recruit new oncology faculty with Winship.
The new director comes to the Aflac Cancer Center having previously served as professor of pediatrics and immunology at the University of Colorado, with clinical practice at Children's Hospital Colorado. While there, Dr. Graham led the Biology and Treatment of Childhood Cancer Research emphasis area. In this capacity, he directly oversaw all basic science, translational and clinical oncology research for the Center for Cancer and Blood Disorders at Children's Hospital Colorado.
Dr. Graham is a National Institutes of Health-funded investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He was the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.
http://news.emory.edu/stories/2015/09/new_chief_aflac_cancer_and_blood_disorders_center/index.html
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham, Deborah DeRyckere, Kurtis D. Davies & H. Shelton Earp
Affiliations
Corresponding author
Nature Reviews Cancer
14,
769–785
(2014)
doi:10.1038/nrc3847
Published online
24 November 2014
Abstract
Abstract• References• Author information• Supplementary information
The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies. Rather than functioning as oncogenic drivers, their induction in tumour cells predominately promotes survival, chemoresistance and motility. The unique mode of maximal activation of this RTK family requires an extracellular lipid–protein complex. For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages. This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization. In tumours, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumour cell and favour an anti-inflammatory, immunosuppressive microenvironment. Thus, TAM kinase inhibition could stimulate antitumour immunity, reduce tumour cell survival, enhance chemosensitivity and diminish metastatic potential.
Affiliations
University of Colorado Comprehensive Cancer Center, Department of Pediatrics, School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA.
Douglas K. Graham, Deborah DeRyckere & Kurtis D. Davies
University of North Carolina Lineberger Comprehensive Cancer Center, Departments of Medicine and Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
H. Shelton Earp
Competing interests statement
D.K.G. and H.S.E. are co-founders of Meryx, Inc., a company developing small-molecule MERTK kinase inhibitors. D.D. holds stock in Meryx, Inc.
Corresponding author
Correspondence to:
H. Shelton Earp
Author details
Douglas K. Graham is Professor of Paediatrics at the School of Medicine, University of Colorado Denver, Anschutz Medical Campus, USA, and a paediatric oncologist at Children's Hospital Colorado. His work has focused on understanding the normal cellular functions of MERTK and AXL, as well as the potential for MERTK as a therapeutic target in multiple cancer types. Douglas K. Graham's homepage.
Deborah DeRyckere received her Ph.D. from the University of California, Berkeley, USA, and is currently Senior Research Associate in Douglas K. Graham's laboratory. Her work focuses on roles for MERTK in haematological malignancies, novel animal leukaemia models for the evaluation of therapeutic agents and the development of small-molecule and biological TYRO3, AXL and MERTK (TAM) receptor tyrosine kinase inhibitors for the treatment of cancer and other diseases.
Kurtis D. Davies is Research Instructor in Douglas K. Graham's laboratory. He received his Ph.D. in Pharmacology from the University of Colorado, Denver, USA, and went on to do two postdoctoral fellowships studying oncogenic kinases in various cancer types. His current research focuses on exploring the potential clinical utility of small-molecule MERTK and AXL inhibitors in non-small-cell lung cancer.
H. Shelton Earp, former Director of University of North Carolina Lineberger Cancer Center, USA, has studied cancer signalling for 40 years. His laboratory with his then M.D. Ph.D. student and long-term collaborator Douglas K. Graham identified MERTK. Ed Liu's laboratory next door in the Lineberger building identified AXL nearly simultaneously. With many collaborators from the University of North Carolina, the University of Colorado and other institutions, his laboratory has elucidated the physiological and neoplastic roles of MERTK and other tyrosine kinases.
http://www.nature.com/nrc/journal/v14/n12/abs/nrc3847.html#affil-auth
AI
